Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Michèle Milella

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3826-5237; OpenAlex author ID A5023848359. Sources: ClinicalTrials.gov.

Their work

Papers
69 (first author 2, last author 8)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
219
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 13 papers · 2021: 12 papers · 2022: 6 papers · 2023: 10 papers, 1 trial · 2024: 2 papers · 2025: 4 papers · 2026: 7 papers

Papers 50 of 69

  1. Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single-Arm, Feasibility Trial. Co-author DOI 10.1002/cam4.71631↗
  2. Can Machine Learning Predict Metastatic Sites in Pancreatic Ductal Adenocarcinoma? A Radiomic Analysis. Co-author DOI 10.1007/s10278-025-01627-y↗
  3. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  4. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  5. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  6. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  7. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  8. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  9. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional … First author DOI 10.1016/j.esmoop.2024.104001↗
  10. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  11. Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment. Co-author DOI 10.3390/cancers17183014↗
  12. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. First author DOI 10.1002/cam4.7345↗
  13. Stage Classification and Prognosis Assessment in Localized Pancreatic Cancer: It Takes Two to Tango. Co-author DOI 10.1200/jco.23.02494↗
  14. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  15. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  16. Exploring the feasibility of a combined exercise program for patients with advanced lung or pancreatic cancer. Co-author DOI 10.1016/j.apjon.2023.100298↗
  17. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  18. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  19. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  20. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  21. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  22. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  23. Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment. Co-author DOI 10.3390/cancers15051454↗
  24. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  25. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  26. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  27. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(22)00448-x↗
  28. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  29. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Co-author DOI 10.1080/14728222.2022.2021397↗
  30. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  31. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcin… Co-author DOI 10.1016/j.clon.2020.06.019↗
  32. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  33. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  34. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  35. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  36. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Co-author DOI 10.1186/s12885-021-07877-7↗
  37. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  38. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.662205↗
  39. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Last author DOI 10.3389/fonc.2021.688889↗
  40. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Co-author DOI 10.3390/cancers13133119↗
  41. Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i9.885↗
  42. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution? Co-author DOI 10.1007/s13304-020-00798-3↗
  43. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  44. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. Co-author DOI 10.1186/s13046-020-01732-6↗
  45. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  46. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-020-08515-5↗
  47. ASO Author Reflections: Preoperative Nutritional Care: The 'Cinderella' of Surgical Management in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08547-x↗
  48. Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. Co-author DOI 10.2144/fsoa-2020-0165↗
  49. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to … Co-author DOI 10.3389/fonc.2020.600940↗
  50. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers12020275↗

Trials 1

  1. FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma Principal investigator NCT05466799↗

Closest collaborators

The 25 strongest of 219 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giuseppe Malleo · 22 shared papers, 1 shared trial, 2020–2026 · strength 3.37
  2. Roberto Salvia · 22 shared papers, 2019–2026 · strength 2.73
  3. Michele Reni · 18 shared papers, 2011–2026 · strength 2.19
  4. Aldo Scarpa · 20 shared papers, 2011–2025 · strength 2.12
  5. Salvatore Paiella · 15 shared papers, 2020–2025 · strength 1.83
  6. Claudio Bassi · 17 shared papers, 2013–2023 · strength 1.77
  7. Claudio Luchini · 13 shared papers, 2019–2025 · strength 1.58
  8. Marina Macchini · 10 shared papers, 2021–2026 · strength 1.57
  9. Giulia Orsi · 10 shared papers, 2021–2026 · strength 1.55
  10. Letizia Procaccio · 9 shared papers, 2023–2026 · strength 1.55
  11. Ilario Giovanni Rapposelli · 9 shared papers, 2021–2026 · strength 1.38
  12. Giampaolo Tortora · 11 shared papers, 2011–2026 · strength 1.30
  13. Ilaria Trestini · 9 shared papers, 2020–2026 · strength 1.29
  14. Elisa Giommoni · 9 shared papers, 2020–2025 · strength 1.21
  15. Rita Teresa Lawlor · 10 shared papers, 2016–2025 · strength 1.19
  16. Silvia Bozzarelli · 7 shared papers, 2021–2026 · strength 1.13
  17. Sara Lonardi · 7 shared papers, 2023–2026 · strength 1.12
  18. Mariacristina Di Marco · 7 shared papers, 2021–2026 · strength 1.11
  19. Massimo Falconi · 7 shared papers, 2011–2026 · strength 1.03
  20. Mario Scartozzi · 6 shared papers, 2021–2026 · strength 0.93
  21. Vincenzo Corbo · 8 shared papers, 2017–2025 · strength 0.93
  22. Guido Giordano · 7 shared papers, 2021–2025 · strength 0.88
  23. Davide Melisi · 9 shared papers, 2011–2024 · strength 0.86
  24. Sara Pilotto · 5 shared papers, 2020–2026 · strength 0.75
  25. Alice Avancini · 5 shared papers, 2020–2026 · strength 0.75

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.